Clinical trials: Patients With Advanced Solid Tumors
Advanced Solid Tumors
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
This is a phase I study of the safety, tolerability, pharmacokinetics profile, and preliminary efficacy of TT-00434 in patients with advanced solid tumors.
- Trial name
- NCT04830501
- Testing
- TT-00434
- Where
- 3 sites in Taiwan
- Volunteers
- 11 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Advanced Cancer, Solid Tumors
Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
The primary objective of this study is to determine the largest dose of ON 01910.Na (rigosertib sodium) that can be given safely as a 3-day continuous infusion once every 2 weeks (2-week cycle) in patients with advanced cancer.
- Conditions
- Advanced Cancer, Solid Tumors, Cancer, Neoplasms
- Trial name
- NCT01538537
- Testing
- rigosertib sodium
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Traws Pharma, Inc.
Advanced Solid Tumor
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B.
- Trial name
- NCT01455571
- Testing
- HM781-36B
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Advanced Solid Tumors
A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas
The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.
- Trial name
- NCT01163071
- Testing
- ABI-011
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene
cMET-dysregulated Advanced Solid Tumors
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
- Trial name
- NCT02626234
- Testing
- INC280, digoxin, rosuvastatin
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Solid Cancer
A Study of HS-20124 in Patients with Advanced Solid Tumors
HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo.
- Trial name
- NCT06763159
- Testing
- HS-20124 (Phase Ia：Dose escalation ), HS-20124 (Phase Ib: Dose expansion)
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Hansoh BioMedical R&D Company
Solid Tumors
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.
- Trial name
- NCT06727812
- Testing
- HRS-6208
- Where
- 2 sites in China
- Volunteers
- 206 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
- Trial name
- NCT02499328
- Testing
- AZD9150, MEDI4736, AZD5069
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Advanced Solid Tumours, Small Cell Lung Cancer
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy…
- Trial name
- NCT04434482
- Testing
- IMP4297(senaparib)
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 59 people
- Sponsor
- Impact Therapeutics, Inc.
Advanced Solid Tumors
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.
- Trial name
- NCT06963398
- Testing
- HS-10529
- Volunteers
- 520 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Non-Small Cell Lung Cancer, Other Solid Tumors
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
The purpose of this study is to evaluate how safe VELCADE (PS-341) is when given with Taxotere (Docetaxel) to patients with non-small cell lung cancer or other solid tumors, and also to see what effects (good and bad) it has on…
- Trial name
- NCT00064636
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Volunteers
- 46 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Advanced Solid Tumor
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with…
- Trial name
- NCT07226349
- Testing
- BG-75098, BGB-43395, Fulvestrant
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 105 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumors
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
- Trial name
- NCT01529307
- Testing
- TAS266
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
Study Of ATRN-119 In Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid…
- Trial name
- ABOYA-119 (NCT04905914)
- Testing
- ATRN-119
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Aprea Therapeutics
Solid Tumor Malignancies
GKL-006Allo Injection in Patients With Advanced Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.
- Trial name
- NCT07704515
- Testing
- GKL-006Allo Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Advanced Solid Tumors
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors.
- Trial name
- NCT05701709
- Testing
- SHR-A2102
- Where
- China
- Volunteers
- 395 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Solid Tumor, Locally Advanced Solid Tumor
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose…
- Conditions
- Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05717348
- Testing
- ES014
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.